柳丹博士現(xiàn)任鼎暉投資高級(jí)合伙人,負(fù)責(zé)健康醫(yī)療領(lǐng)域的投資,代表項(xiàng)目包括:成都先導(dǎo)(688222.SH)、天境生物(IMAB.O)、和鉑醫(yī)藥-B(2142.HK)、九強(qiáng)生物·邁新生物(300406)、集萃藥康、新格元生物、齊碳科技等。 在加入鼎暉投資前,柳博士曾在Bain & Company從事大健康領(lǐng)域和大消費(fèi)領(lǐng)域的管理咨詢業(yè)務(wù)。期間,他服務(wù)并負(fù)責(zé)過(guò)多個(gè)大型跨國(guó)醫(yī)藥和器械企業(yè)的戰(zhàn)略項(xiàng)目。 柳丹博士在科研、商業(yè)、管理、咨詢、投資等多領(lǐng)域擁有近二十年健康醫(yī)療行業(yè)相關(guān)經(jīng)驗(yàn)。 柳丹博士同時(shí)擔(dān)任多個(gè)政府、行業(yè)協(xié)會(huì)理事和高級(jí)專家,及多個(gè)省市級(jí)科技和人才項(xiàng)目的審評(píng)專家。獲評(píng)“投資界2021 F40中國(guó)青年投資人”、“2021年度最佳醫(yī)療大健康領(lǐng)域投資人物TOP 10”、“醫(yī)療健康投資卓悅榜40 Under 40.年度醫(yī)療健康投資人”、“未來(lái)醫(yī)療100強(qiáng).年度青年投資人”。 ? Dr. Dan LIU is the Senior Partner at CDH Investments, in charge of Healthcare Investments of Venture and Growth Capital. Dr. LIU has led a series of life science investments, including HitGen (688222.SH)、I-Mab (IMAB.O)、Harbour BioMed (2142.HK)、Maxim Biotechnologies (300406), and currently sits on board of nearly 20 portfolio companies. Prior to joining CDH, Dr. LIU has successively worked at a number of multi-national corporations as management roles and extensive experience in domestic and cross-border healthcare industries. He was the former key professional of Asia Healthcare practice at Bain and Company. Dr. Liu is a seasoned scientist, consultant and investor with nearly 20 years of experience in Healthcare Sector. |